Drug Profile
TK 002
Alternative Names: TK-002Latest Information Update: 28 Oct 2023
Price :
$50
*
At a glance
- Originator Takis
- Class Antineoplastics; Cancer vaccines
- Mechanism of Action Immunostimulants; Neoplasm antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for preclinical development in Cancer in Italy
- 28 Aug 2020 No recent reports of development identified for preclinical development in Colorectal-cancer in Italy
- 28 Aug 2020 No recent reports of development identified for preclinical development in Gastric-cancer in Italy